MiR 208a Regulates Mitochondrial Biogenesis in Metabolically Challenged Cardiomyocytes

Area of Science:

• Cardiology
• Molecular Biology
• Metabolic Disease Research

Background:

• Metabolic syndrome elevates cardiovascular disease risk, including metabolic cardiomyopathy.
• Declining mitochondrial metabolism is a key factor in heart failure progression.
• MicroRNA 208a (miR 208a) is cardiac-specific and hypothesized to influence cardiomyocyte bioenergetics.

Purpose of the Study:

• To investigate the role of miR 208a in regulating human cardiomyocyte bioenergetic metabolism under metabolic stress.
• To identify specific miR 208a targets involved in mitochondrial function.

Main Methods:

• In silico screening for miR 208a targets related to mitochondrial function.
• CRISPR-mediated deletion of miR 208a in human SV40 cardiomyocytes.
• Exposure of cardiomyocytes to high glucose and high albumin-bound palmitate.
• Analysis of protein expression, myosin heavy chain α, mitochondrial biogenesis markers, mtDNA, and respiratory function.
• Reinsertion of miR 208a to confirm effects.

Main Results:

• miR 208a deletion rescued specific mRNA targets involved in nuclear transcription, mitochondrial translation, and integrity.
• Suppression of miR 208a prevented metabolic stress-induced decreases in cardiac contractility markers (myosin heavy chain α).
• miR 208a deficiency opposed metabolic challenge-induced declines in mitochondrial biogenesis, mtDNA, and respiratory function, with effects reversed upon miR 208a reinsertion.

Conclusions:

• miR 208a plays a significant role in regulating mitochondrial biogenesis and function in cardiomyocytes under diabetic conditions.
• Targeting miR 208a could be a therapeutic strategy to enhance mitochondrial function in chronic diseases with mitochondrial defects.